GLP-1 Drugs for Obesity: EU Reimbursement Guide
GLP-1 reimbursement Europe policies are transforming obesity treatment access across the EU. This guide covers coverage for drugs like semaglutide and tirzepatide. Understanding reimbursement helps clinicians support patient adherence and outcomes.
Cannabis cheaper and more available than ever, study finds| Ryan Bridge TODAY
Increased cannabis availability clinical implications extend beyond simple access, fundamentally altering medical cannabis prescribing considerations. Clinicians must adapt monitoring protocols as market dynamics shift therapeutic landscapes.…
GLP-1 Medicare Coverage: $50 Monthly Copay Starting July 2026
Medicare coverage expansion GLP-1 programs will reduce costs for eligible beneficiaries starting July 2026. This initiative offers a $50 monthly copay for semaglutide, enhancing access to effective weight management therapies. The policy supports better…
Understanding the Medicare GLP-1 Bridge Program for Obesity
The Medicare GLP-1 Bridge program expands access to GLP-1 receptor agonists for obesity treatment among Medicare beneficiaries. This policy reduces barriers and improves coverage for effective weight loss medications. It enables clinicians to offer…
Study Finds Cannabis Knowledge Gaps Among Thai Border Patients
A 2025 study reveals significant cannabis knowledge public health education gaps among patients near the Thai-Cambodian border. Over 60% could not identify safe uses or side effects of cannabis despite legalization. This highlights urgent needs for…
State Cannabis Revenue Slow to Reach Communities
Cannabis tax revenue community reinvestment was designed to support substance abuse treatment and mental health services in affected areas. However, delays and administrative hurdles have slowed the return of these funds to communities. This impacts…